Expertise in
11
conditions

Dr. Sukhmani K. Padda

Oncology
Temple Faculty Practice Plan Inc
333 Cottman Ave, 
Philadelphia, PA 
Expertise in
11
conditions
Temple Faculty Practice Plan Inc
333 Cottman Ave, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sukhmani Padda is an Oncologist in Philadelphia, Pennsylvania. Dr. Padda is highly rated in 11 conditions, according to our data. Her top areas of expertise are Thymic Epithelial Tumor, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Thymectomy.

Her clinical research consists of co-authoring 80 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Temple University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

TEMPLE FACULTY PRACTICE PLAN INC
333 Cottman Ave, Philadelphia, PA 19111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Necitumumab, Osimertinib
Study Phase: Phase 1
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer
An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Biological
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: December 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]
Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Drug, Other
Study Drugs: Methotrexate, Regorafenib
Study Phase: Phase 2
Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC With Acquired Resistance to First or Third Generation EGFR TKIs
Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC With Acquired Resistance to First or Third Generation EGFR TKIs
Enrollment Status: Terminated
Publish Date: April 14, 2022
Intervention Type: Other, Biological, Drug
Study Drugs: Afatinib, Necitumumab
Study Phase: Phase 1
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
View 8 Less Clinical Trials

80 Total Publications

Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: June 16, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Corey J. Langer
Oncology
Expertise in
14
conditions
Dr. Corey J. Langer
Oncology

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (10.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Corey Langer is an Oncologist in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Langer is currently accepting new patients.

Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology | Hematology Oncology | Hematology
Expertise in
27
conditions
Dr. Jakub Svoboda
Oncology | Hematology Oncology | Hematology

University Of Penn-Medical Group

3400 Civic Ctr Blvd, 
Philadelphia, PA 
 (10.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 27 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
28
conditions
Dr. Pierluigi Porcu
Oncology | Hematology Oncology | Hematology
Expertise in
28
conditions
Dr. Pierluigi Porcu
Oncology | Hematology Oncology | Hematology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (9.0 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Pierluigi Porcu is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Porcu is highly rated in 28 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Padda's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile